Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Compared with tirzepatide, Wegovy (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) while on treatment 1 Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment 1 The findings support growing evidence that the established CV benefit seen with Wegovy is specific to the semaglutide molecule and therefore cannot be generalized to the GLP-1 or GIP/GLP-1-receptor agonist classes 1 -- Novo Nordisk presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain
Purity: 97.2 % EXPERIMENTAL PORTION The details of the invention are given in the examples provided below, which are given to illustrate the invention only and therefore should not be construed to limit the scope of the invention
Storage: Store in a cool, dry place, without direct sunlight
Long-term safety is uncertain
10.1345/aph.1Q789 34 GagnonA
